May 16, 2013
- Roche today announced the first results from CLL11, a phase III study of the investigational medicine GA101 which is being conducted in collaboration with the German CLL Study Group (GCLLSG).
- •Three of the company’s investigational compounds, targeting different pathways and distinct patient populations, will be included in 14 data presentations• Four abstracts accepted for oral presentation – spanning advanced non-small cell lung cancer (NSCLC), renal cell carcinoma, head and neck squamous cell carcinoma and ovarian cancer
- Growing body of clinical data supports superiority of the irreversible ErbB Family Blocker afatinib* over standard chemotherapy (with combination of cisplatin and gemcitabine or pemetrexed) for first-line treatment of patients with EGFR-mutation positive advanced NSCLC First set of Phase III results unveiled from LUME-Lung clinical trial programme investigating triple angiokinase inhibitor nintedanib* in advanced NSCLC - For non U.S. Media Only
May 15, 2013
- A clinical trial has shown that patients, and their physicians, are eager to jump into next-era cancer care - analysis of an individual's tumor to find and target genetic mutations that drive the cancer. Results of the study, CUSTOM, are being presented at the 2013 annual meeting of the American Society of Clinical Oncology years before investigators thought they would be ready.
- The U.S. Food and Drug Administration today approved a new use for Simponi (golimumab) injection to treat adults with moderate to severe ulcerative colitis.
- Tarceva is the first personalised medicine approved for the initial treatment of people with EGFR mutation-positive advanced non-small cell lung cancer in the United States.
- The U.S. Food and Drug Administration today approved Xofigo (radium Ra 223 dichloride) to treat men with symptomatic late-stage (metastatic) castration-resistant prostate cancer that has spread to bones but not to other organs. It is intended for men whose cancer has spread after receiving medical or surgical therapy to lower testosterone.
SOUTH SAN FRANCISCO, Calif. and NORTHBROOK, Ill. – May 14, 2013 – Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) and Astellas Pharma US, Inc. (“Astellas”), a U.S. subsidiary of Tokyo-based Astellas Pharma Inc. (Tokyo: 4503), today announced that the U.S. Food and Drug Administration (FDA) has approved Tarceva® (erlotinib) tablets for the initial (first-line) treatment of people with...
- First phase III data on obinutuzumab (GA101) in one of the most commonly diagnosed blood cancers; Early stage data on investigational anti-PDL1 immunotherapy